Toxicokinetic (TK) studies are the basis for demonstrating dose-related drug exposure in animals and for ensuring that drug exposure is substantially greater in animals than that expected in humans at therapeutic doses. The usefulness of TK studies can be further enhanced by correlating TK parameters with relevant toxicologic end points. The so-called TK/toxicodynamic (TD) correlations can be extremely useful in bridging data from studies both within and across species and in designing early Phase I clinical trials. These correlations assume that toxicologic responses are comparable among species at comparable plasma concentrations. This assumption may apply for certain drugs but not for others. Therefore, TK/TD correlations should be developed and utilized on a case-by-case basis. Such correlations have proven to be extremely useful with anticancer drugs in formulating dose escalation strategies in cancer patients to rapidly attain the maximum tolerated and/or effective dose. However, these correlations have not been utilized effectively in other therapeutic areas. The development of TK/TD correlations, their scope, and limitations are discussed in this paper.
INTRODUCTION
Toxicokinetic (TK) studies are an essential tool in drug development. Preclinical subchronic and chronic toxicology studies are routinely monitored for plasma drug and/or metabolite concentrations to assure that the animals are being exposed to the drug and that the exposure is dose-related. These analyses are usually performed on day I and at steady state near the end of the study, which enable the determination of whether or not the drug has the potential to either accumulate or induce its own metabolism upon multiple dosing. The pharmaceutical industry is striving to meet these goals, especially with regard to correlating drug exposure with toxicologic findings. TK/toxicodynamic (TD) correlations, if successfully developed, may enable useful extrapolation of data from animals to humans.
A BASIC AssUMPTION
When extrapolating data from animals to humans, the basic assumption is made that the plasma drug concentration-effect relationships are similar across species. This assumption is valid for many drugs, and a classic example is that of hexobarbital (13) . The pharmacokinetics of hexobarbital are significantly different in the rat, rabbit, and mouse. The half-life is short in the mouse, intermediate in the rabbit, and long in the rat. Consequently, the duration of effect (sleeping time) following intraperitoneal administration of 50-100 mg hexobarbital/ kg is longest in the rat (90 min) and shortest in the mouse (19 min). However, when the animals awaken from the effect of the drug, the plasma drug concentrations are similar in all species, indicating that the concentration-effect relationship for hexobarbital is similar across species.
Similar correlations have been established for many other drugs (Table I ). The pharmacokinetics of phenytoin are different in the rat, rabbit, dog, and human; however, neurotoxicity in all of these species is observed when plasma phenytoin concentrations exceed 30 4g/ml (8) . Nilvadapine, a calcium channel blocker, undergoes extensive first-pass metabolism in dogs but not in humans; nevertheless, in both species, a 20% lowering in the blood pressure occurs at a plasma nilvadapine concentration of around 20 ng/ml (15) . In ( 1 )]. a plasma concentration of about 3 Ag/ml (6) . Similarly for phenylbutazone, both its anti-inflammatory effect and the sodium retention effect occur at a similar plasma drug concentration in both rats and humans. The maximum tolerated dose (MTD) of the anticancer drug doxorubicin is 90 mg/m2 in humans and 18 Mg/M2 in rabbits (LD,o). Although there is a 5-fold difference in dose, the plasma doxorubicin concentrations at these equitoxic doses, as shown in Fig. 1 , are similar (5) . Many other drugs demonstrate similar phenomena, assuring that it may be feasible to develop TK/TD correlations that will enable the extrapolation of data from animals to humans. This paper will present 2 examples of drugs for which TK/TD correlations were developed and utilized to select initial and/or limiting doses in clinical trials.
APPROACH WITH AN ANTIVIRAL DRUG
The first example is that of an anti-viral compound similar in chemical structure to azidothymidine (AZT), which will be referred to as Compound A. The development goal was to expedite the clinical evaluation of the drug and its use in AIDS patients as expeditiously as possible. Preclinical TK/TD correlations were utilized to attain this goal, which sig-nificantly aided in selecting the initial dose in humans and in reducing the Phase I drug development time.
AZT and analogous compounds exhibit hematologic toxicity in both animals and humans. In a 1-mo toxicology study with Compound A in the cynomolgus monkey, both the drug exposure and changes in the red blood cells (RBCs) were determined. The data revealed a meaningful correlation between drug exposure and hematologic toxicity. The percentage of change in RBC counts from baseline increased proportionally with dose (and drug exposure), resulting in an 8-10% change in RBCs associated with a dose of 5 mg/kg/day. The corresponding drug exposure as determined by the area under the plasma drug concentration-time curve (AUC) at this dose was about 6 pg -hr/ml. Assuming that the monkey is a good animal model for predicting hematologic toxicity in humans, and that an 8-10% change in the RBC count is clinically acceptable, then drug exposure in humans at an initial selected dose should not exceed 6 gg -hr/ml. Consequently, based on the available animal data, what dose would be required in humans to provide equivalent exposure? A few pharmacokinetic equations can be readily derived and used to answer this question.
The AUC in animals and humans can be represented by the following 2 equations:
A~~human -(Fhuma. XDhuman)/C4uman3 (2) where F is the fraction of the drug that reaches the systemic circulation, D is dose, and CL is total body clearance. To attain equivalent AUC (exposure) in animals and humans, the right-hand side of Equations 1 and 2 can be equated and simplified as follows :
This equation indicates that the dose needed in humans that would result in the same AUC (exposure) as that in animals is equal to the dose in animals corrected for the differences in F and CL in the 2
species.
A key unknown in Equation 3 is the CL value in humans, because the drug has not yet been administered to humans. How then does one determine or estimate the clearance in humans? One approach is allometry (7) , which is based on the principle that physiological and pharmacokinetic variables between species can be related to their body weight, expressed as follows:
where Y is the physiological or pharmacokinetic variable, a is the allometric coeflicient, W is the body weight, and b is the allometric exponent. The equation indicates that the value of a physiological variable increases with the size (body weight) of the species. An excellent review of allometry was published by Mordenti and Chappell (9) . This principle is simple, requires data that are commonly available during preclinical drug development, and has been utilized extensively in extrapolating pharmacokinetic data from animals to humans. The approach has been used for a variety of drugs; however, it usually works best with drugs that are not extensively metabolized.
The preferred approach is to administer a small dose to humans, determine the resulting plasma drug concentrations, calculate AUC (for clearance), and compare it to that in animals at toxicologic doses.
Based on the actual drug exposure in humans and its correlation to the critical drug exposure in ani-mals, one can select dosing regimens to be used in the early clinical trials. Critical exposure is defined as that AUC in animals that corresponds to a certain degree of toxicity that should not be exceeded in humans. This approach is being used extensively in the development of anticancer drugs. For example, Collins et al (4) showed that the AUC obtained in the mouse at the LD,o dose is a good predictor of the AUC in humans at the MTD. Based on this finding, the usual starting dose in patients in Phase I clinical trials is about one-tenth of the LD,o dose in the mouse. Consequently, if the AUC in patients at the initial dose is significantly lower than that in the mouse, at the LD,o dose, then the clinical doses can be escalated in larger increments, which can save considerable development time in identifying the MTD in humans.
The allometric approach was used to estimate the clearance (CL) of Compound A in humans. Patel et al (11) showed that for antiviral drugs such as AZT an excellent correlation could be developed between the clearance of AZT and body weight between many laboratory species and, based on the regression equation, clearance was estimated in humans. Because Compound A is analogous to AZT, the allometric approach was used to establish the relationship between the total body clearance (CL/F) of A and the body weight in the rat, dog, monkey, and human, as shown in Fig. 2 , wherein 2 clearance values are shown for humans: one that was projected from allometry, and the other that was obtained when the drug was actually administered to humans.
The correlation between the 2 values was excellent.
Once an estimate of the clearance was obtained, Equation 3 was used to project a dose in humans that would give the desired AUC (or exposure). Safety evaluation studies in the monkey using Compound A indicated that a dose of 5 mg/kg/day was associated with a clinically relevant toxic end point in the monkey. The allometric scaling of oral clearance values from the rat, dog, and monkey yielded a predicted oral clearance of 0.3 L/hr/kg for a 70kg human as compared to the observed value of 0.9 L/hr/kg in the monkey. Based on complete absorption, uniformity, and linearity of the TK data across species, F in the monkey and human was assumed to be equal. Thus, the dose in humans that could result in an AUC equal to that after a dose of 5 mg/ kg/day in the monkey was calculated as follows:
Dh&dquo;mans = 5 mg/kg/day x [(0.3 L/hr/kg)/(0.9 L/hr/kg)]
The projected dose in humans that was chosen for the multiple dose safety and tolerance clinical trials was thus close to 1.7 mg/kg/day. APPROACH WITH AN ANTIPSORIATIC AGENT
The second example is of a topical antipsoriatic agent, Compound B (Fig. 3) , which is under development at Schering-Plough. Compound B is believed to exert its pharmacological effect topically (locally); hence, it is desirable that the drug not be absorbed from the application site. However, this is often difficult to control because transdermal absorption depends on both the physicochemical characteristics of the drug and the delivery vehicle in which it is formulated. Nevertheless, if the drug is absorbed percutaneously, it raises clinical issues because the amount of drug that can be applied on the skin will depend on the degree of absorption, the resulting exposure, and the relationship between the exposure and toxicity.
The pharmacokinetic data and gross observations made from the 3-mo toxicology study in dogs with Compound B applied topically at doses of 0.5, 1, 2, and 5 mg/kg/day is shown in Table II . With the exception of a small loss in the body weight, no remarkable toxicologic findings were observed at the 3 lower doses; however, at the 5-mg/kg dose, in addition to the body weight loss, emesis was observed. Therefore, a dose of 5 mg/kg was considered to be the MTD in the dog. The projected drug exposure of total drug-derived material at this dose in the dog, based on pharmacokinetic studies with the radiolabeled (14 C) active Compound A was 7,200 ng eq ~ hr/ml. Assuming that the dog is an appropriate animal model of toxicity for this compound, then in humans an AUC exposure value of 7,200 ng eq-hr/ml should not be exceeded. An antipsoriatic drug intended for topical use should allow for an adequate margin of safety to minimize possible human toxicity. Based on inherent variability in the toxicokinetic data and the type of toxicological findings, a 10-fold margin of safety was considered adequate. Hence, the systemic drug exposure in humans for Compound B should not exceed 720 ng eq. hr/ml. The 2 formulations of clinical interest for Compound B were a 0.1 and 1 °lo cream. The question, therefore, was, What is the maximum amount of cream that may be applied to humans so as not to exceed the limiting exposure of 720 ng ed -hr/ml?
The allometric approach may not be reliable with Compound B because it undergoes extensive metabolism in animals and humans. Additionally, the allometric approach has not been tested with dermal products; therefore, the preferable approach would be to evaluate the absorption of a small amount of 14C-labeled-B in humans using the individual creams. Consequently, a study was undertaken in which 12 mild to moderate psoriatic patients were enrolled. Six patients were used to evaluate the absorption of the 0. I °lo cream and another 6 to evaluate the absorption of the 1 % cream. Approximately I g of the cream was applied on either arm or trunk of the patients to cover a 100-cm2 psoriatic area for a 12hr period, after which the cream was gently wiped off from the application site. Plasma, urine, and fecal samples were collected at specified time points for up to 7 days after the application.
Radiolabeled formulations were used in this study for 2 reasons: (a) a chemical assay was not yet available, and (b) because the elicited toxicity may be due to both the parent drug and metabolites, it was considered appropriate to use the labeled ('4C) compound. The results from the study are shown in Table III . Based on the urinary and fecal excretion of total radioactivity, the percentage of drug absorbed in humans was 33% from the 0.1% cream and 19% from the 1 % cream. The corresponding exposure (AUC) was 141 ng eq ~ hr/ml from 1 g of the 0.1 °1o cream and 838 ng ed. hr/ml from I g of the 1% cream. If the limiting exposure in humans is --~ 720 ng eq -hrlml (based on toxicology data in the dog), then the maximum amount of 0.1 % cream that may be applied in clinical trials is about 5 gIday. Based on similar calculations. the corresponding amount for the 1 % cream that may be applied is about 1 g/day, which is not adequate to cover the entire skin area to treat psoriases. Hence, it was decided to use up to 5 g, day of the 0. I °lo cream in psoriatic patients in clinical trials. The 1°~O cream was dropped from further development. FAcroRs THAT MAY AFFECT TK/TD CORRELATIONS Factors such as route of drug administration, protein binding, mechanism of toxicity, metabolism, and so forth must be considered in establishing TK/ TD correlations. The route of drug administration in toxicology studies should mimic that intended to be used in humans. For some drugs, toxicity may be related to a certain threshold plasma drug concentration. In such cases, the frequency of dosing may also affect the TK/TD correlations. For example, Powell et al (12) showed that nephrotoxicity in dogs after continuous administration of gentamicin and tobramycin by intravenous infusion is significantly higher than that after administration of the drug every 4 hr as intravenous bolus. Administration of 45 mg gentamicin/kg/day to dogs for 10 days reduced their glomerular filtration rate by 86% when the drug was infused continuously and only 29% when given every 4 hr. Similarly, administration of 45 mg tobramycin/kg/day for 10 days to dogs reduced their glomerular filtration rate by 40% when the drug was infused continuously, by 31 % when given every 4 hr, and by 12% when given once daily. It appears that for these drugs the toxicity is related to the duration of drug exposure over a certain threshold of plasma drug concentration, not to the peak plasma drug concentration. On the other hand, embryotoxicity of valproic acid in mice is much higher when the drug is administered by intravenous bolus compared to that by intravenous infusion (10) . The embryotoxic dose (20% embryotoxicity) was 350 mg/kg/day following bolus intravenous administration and 2,700 mg/kg/day following continuous infusion. For valproic acid, embryotoxicity appears to be related to the peak plasma drug concentration, which is much higher after the rapid intravenous bolus administration.
The hematologic toxicity of the antiviral Compound A discussed earlier in dogs in the 1-mo toxicology studies was significantly higher when the drug was given in 3 equally divided doses (tid) than when it was given as a single dose, once daily (qd) ( Table IV ). The toxicity that resulted from the oncedaily 25-mg/kglday tid dose was similar to that from TABLE IV.-Intensity of hematologic toxicity following 1, 5, or 25 mg/kg/day of Compound A, given by gavage to dogs as a single daily dose (od) or equally divided doses, 3 times a day (tid), for 1 mo. the 5-mg/kg/day tid dose. Mortality was observed in 4 of 8 dogs given 25 mg/kg/day once daily, whereas all dogs given 25 mg/kg/day tid died before the study end. The resulting plasma drug concentrationtime profiles from the qd vs tid dosing regimen were as would be expected from the linear pharmacokinetics of this drug (Fig. 4 ). Compared to the qd administration, the peak plasma drug concentration for the tid administration was about one-third, although the total AUC was the same. It would appear that the toxicity of Compound A was related to the duration of exposure (over a certain threshold plasma drug concentration) rather than to the peak plasma drug concentration.
Protein binding also plays a critical role in establishing TKJTD correlations because, for highly bound drugs, it is the free/unbound drug concentration that better correlates with either the pharmacological or toxicological effects than does total drug. The plasma concentrations of total phenytoin in rats and humans were significantly different at the time of onset of ataxia. However, the concentrations of the free/unbound phenytoin were similar when ataxia occurred, i.e., ~ 6 mg/L, in both the rats and humans (14) . Therefore, species-and concentration-related differences in protein binding must be considered for any valid extrapolations from animals to humans.
When the plasma drug concentrations are not in equilibrium with tissue drug concentrations, then the plasma drug concentrations do not correlate with pharmacological or toxicological effect. In the case of a diuretic Bumex ~ (bumetanide), the pharmacodynamic effect correlates better with unchanged drug in the kidney (7) . Although a dose of 20 mg/ kg is ineffective in the rat, nevertheless even a small dose of 0.015 mg/kg is very effective in producing diuresis in humans. The explanation is that only 3% of the administered dose is excreted in urine in rats as compared to 66% in urine in humans. Because the diuretic effect correlates with unchanged drug in the kidney, the drug is a potent diuretic in humans but not in rats. For such a drug, it would not be possible to extrapolate data from animals to humans.
In establishing a TK/TD correlation from toxicology data, it is assumed that the monitored or observed toxicological effect on animals would also be observed in humans. However, this may not always be true. The anti-inflammatory compound ICI 54,450 was found to be safe in rats and dogs at plasma concentrations significantly above those observed in humans at therapeutic doses, yet humans developed jaundice at therapeutic doses (1). This toxic response was not evident in toxicology studies because rats and dogs do not develop jaundice. Therefore, the mechanism of toxicity in humans did manifest itself in the rat and dog. Thus, a significant factor in developing TK/TD correlation is the identification of a readily detectable TD end point. Because it is difficult to identify such an end point for many drugs, the development of TK/TD correlations sometimes may be more difficult than the development of pharmacokinetic/pharmacodynamic correlations.
With anticancer drugs, it has been shown that the LD,o in mice is a good predictor of the MTD in humans. For most anticancer drugs, the plasma drug concentrations in the mouse at the LD,, and in humans at the MTD are similar (3). However, even in this class of drug there are exceptions. In the case of anticancer compound F-ARA-A, the plasma drug concentrations at equitoxic doses of 2,600 mg/m2 (LD,O) in the mouse, and at 260 mg/m2 (MTD) in humans were not similar, because they were about 10-fold higher in the mouse. Thus, the toxicity in humans occurs at much lower plasma drug concentrations than those in the mouse. In this case, the difference in the mouse and human is because of the difference in the pharmacodynamics of the drug in these divergent species. The human is more sensitive to F-ARA-A than the mouse: hence. any extrapolations based on animal data will be misleading.
CONCLUSIONS
Examples were presented to demonstrate that TK/ TD correlations can be developed and may be used advantageously in drug development. Some investigators may take the optimistic view and assume that animal correlations may always be projected to humans. Others may take the pessimistic view and assume that humans are unique and, therefore, animal data should not be used to extrapolate data to humans. The reality is that TK/TD correlations are valid only on a case-by-case basis; however, when they do work, they can provide an excellent guide in making the transition from preclinical to clinical drug development. Therefore, it is worth the effort to develop and explore such correlations. Many factors may affect these correlations; therefore, caution must be exercised in developing them and in extrapolating data from animals to humans. If careful attention is paid to the factors discussed earlier during the study design and data collection phases, more often than not, correlations may be developed and used cost-effectively in developing new drugs.
